[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-adverse-cardiovascular-events-mace\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-adverse-cardiovascular-events-mace":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642637","prediction-of-myocardial-injury-after-non-cardiac-surgery-in-urologic-cancer-patients-100642637",false,"NCT07634666","Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients","Prediction of Myocardial Injury After Major Non-Cardiac Surgery in Patients With Urologic Cancer: A Prospective Multicenter Observational Study","URO-MINS","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Patients scheduled for major non-cardiac surgery under general anesthesia due to urologic cancer (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy)\n* Patients who undergo preoperative standard 12-lead electrocardiography\n* Patients classified as having intermediate or higher surgical risk\n* Patients who can be followed for at least 30 days postoperatively\n* Patients who voluntarily provide written informed consent to participate in this study\n\nExclusion Criteria:\n\n* History of major adverse cardiovascular events (MACE) within 6 months prior to surgery\n* Inability to obtain essential clinical information required for study participation and follow-up\n* Patients who are not hospitalized after surgery\n* Individuals deemed inappropriate for participation in the study by the investigator due to legal or psychiatric reasons","ALL","60 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days after surgery in patients undergoing non-cardiac surgery for urologic cancer.",[25,26,27],"Myocardial Injury After Non-cardiac Surgery","Urologic Cancer","Major Adverse Cardiovascular Events (MACE)",[29,30,25,31,32,26],"Artificial Intelligence","Electrocardiography","Major Adverse Cardiovascular Events","Perioperative Cardiovascular Risk","NOT_YET_RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":21},"2026-06-01",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"Korea University Anam Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100580876","serial-coronary-cta-based-plaque-progression-detection-for-management-of-coronary-heart-disease-100580876","NCT06843005","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial","SUCCESS","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);\n3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.\n\nExclusion Criteria:\n\n1. Patients who have experienced ACS or PCI\u002FCABG;\n2. Patients who have experienced adverse cardiovascular and cerebrovascular events;\n3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;\n4. Patients with severe hepatic and renal dysfunction;\n5. Patients with contraindications to CCTA examinations;\n6. Patients with poor initial CCTA image quality or data loss.","18 Years","80 Years",{"count":56,"type":21},3100,"INTERVENTIONAL",[59],"NA","The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.",[27,62,63,64],"Prevention","Coronary Artery Disease(CAD)","CT Angiography","RECRUITING","2026-03-19",{"date":68,"type":37},"2026-03-24",{"date":70,"type":37},"2025-02-28",{"date":72,"type":21},"2028-12-30",{"name":74,"class":44},"Zhang longjiang,MD",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":84,"targetDuration":4,"studyType":57,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100619723","vitamin-b-supplementation-for-patients-undergoing-cardiovascular-surgery-100619723","NCT07348328","Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery","Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery: A Randomized Controlled Trial","PANDA XII","Inclusion Criteria:\n\n* Aged 18-80 years, regardless of gender;\n* Scheduled to receive cardiovascular surgery at the research center, including coronary artery bypass grafting (CABG), cardiac valve replacement\u002Frepair, and great vessel surgery;\n* Preoperative assessment indicates that the patient is expected to complete the 6-month postoperative follow-up;\n* The patient or their authorized agent signs a written informed consent form.\n\nExclusion Criteria:\n\n* Regular supplementation with Compound Vitamin B (daily dose ≥ 1.5 times the recommended dietary allowance) or separate supplementation with folic acid, vitamin B6, or B12 within 3 months before surgery;\n* Severe hepatic or renal insufficiency (liver function: ALT\u002FAST \\> 3 times the upper limit of normal, or total bilirubin \\> 2 times the upper limit of normal; renal function: serum creatinine \\> 265 μmol\u002FL, or requiring long-term dialysis treatment);\n* Malignant tumors, severe hematological diseases (e.g., megaloblastic anemia, aplastic anemia), severe malnutrition (albumin \\\u003C 25 g\u002FL);\n* History of allergy to Compound Vitamin B preparations or placebo components; Pregnant women, lactating women, or those planning to become pregnant during the study period;\n* Currently participating in other interventional clinical trials;\n* Moderate to severe cognitive impairment without a fixed caregiver, unable to cooperate with treatment and follow-up;\n* Preoperatively diagnosed with severe infection, septicemia, or septic shock.",{"count":85,"type":21},1000,[59],"This study is a multicenter, randomized controlled, double-blind, placebo-controlled parallel trial designed to evaluate the effect of perioperative supplementation with Compound Vitamin B on patients undergoing cardiovascular surgery. A total of 1,000 patients aged 18-80 years who are scheduled to receive cardiovascular surgeries such as coronary artery bypass grafting (CABG) and valve replacement will be enrolled. They will be randomly assigned at a 1:1 ratio to either the experimental group (perioperative supplementation with Compound Vitamin B tablets, once daily from 3 days before surgery to 6 months after surgery) or the control group (oral placebo), with both groups receiving standardized perioperative treatment.",[89,27],"Cardiovascular Surgical Procedures",[91,92,31],"Compound Vitamin B","Cardiovascular Surgery","2026-01-09",{"date":95,"type":37},"2026-01-16",{"date":97,"type":21},"2026-02-01",{"date":99,"type":21},"2027-12-31",{"name":101,"class":44},"Nanjing Medical University",2]